Inorganic Chemistry Communications, cilt.177, 2025 (SCI-Expanded)
In this study, peripherally tetra-{4-[5-(heptylthio)-4-methyl-4H-1,2,4-triazol-3-yl]phenoxy} group substituted cobalt(II), copper (II) and axially di-{4-[5-(heptylthio)-4-methyl-4H-1,2,4-triazol-3-yl]phenoxy} substituted silicon(IV) phthalocyanines were synthesized via multistep reactions. The structure of new compounds was characterized by FT-IR, 1H NMR, 13C NMR, Mass, andUV–Visible spectroscopy.The compounds were screened in lung (A549) and breast (MCF-7) cancer cell lines for 72 h. The probable anticancer effect mechanism of the synthesized compounds was explored by molecular modeling. The target for compounds with similar scaffold was reported to be topoisomerase I. Hence, molecular docking and molecular dynamics (MD) simulation was conducted to evaluate their binding potential with topoisomerase I. The docking study revealed that TR-C7-Si had the highest binding affinity to the enzyme, which was higher than the standard inhibitor, topotecan. The MD simulation analysis also exhibited that TR-C7-Si formed the complex with the highest stability. In addition, TR-C7-Si is anticipated to remain inside the binding region of the enzyme. The computational study demonstrated that TR-C7-Si would exhibit the highest potential to bind to the enzyme. So, the potential of TR-C7-Si to act by inhibiting topoisomerase I was found to be feasible.